ArticleFrontiers in microbiomes2025
Microbial dysbiosis in melasma through community profiling.
Article in Frontiers in microbiomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The complex ecosystem on skin comprising tens of thousands of microorganisms plays an important role in health and disease. The last decade in particular has witnessed a surge in microbiome research, which has been elucidating the role of the microbiota in numerous skin pathologies. Of relevance to the current study, are recent evidences implicating the microbiome in skin pigmentary conditions. Melasma is one such refractory, hyperpigmentary condition with a poorly understood pathogenesis. The present study was carried out to characterize the nature of microbial dysbiosis and its impact on microbial community structure in melasma subjects. Results: The clinical assessment of melasma carried out using biophysical, biochemical and biomarker-based measures confirmed significant changes in melasma lesions, most notably, those linked to redox, inflammation and barrier properties. A deep characterization of the skin microbiome in melasma from human face, indicated significant differences between lesional and peri-lesional areas. Of the 377 genera identified through an agglomeration of all OTUs at the Genus level through 16S rRNA sequencing, 344 were common, while 12 were unique to lesional and 21 unique in peri-lesional areas. A significant decrease was observed in alpha diversity in melasma lesion as compared to peri-lesion areas, with an accompanying decrease in number of interconnections among them. The differences in the microbiome also appeared to correlate with several clinical parameters, notably with the melasma severity measured through modified MASI (mMASI) scoring. The observed changes in both host and microbiome, point to a potential role for the latter in melasma pathogenesis. Conclusions: Our study indicates that there are significant differences in the microbiome between lesional and peri-lesional areas of melasma subjects, with associated changes in microbial community structures. Additionally, the observed changes were seen to correlate with measured clinical parameters. These findings provide the opportunity to further probe the nature of host and microbiome links that may underlie the phenotypic manifestation, as well as provide effective routes for managing this recalcitrant disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.